Corbenic Partners’s DexCom DXCM Stock Holding History

Corbenic Partners’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-68	Closed	-$9K	–	247
2021 Q4	$9K	Hold	68	–	–	﹤0.01%	177
2021 Q3	$9K	Hold	68	–	–	﹤0.01%	174
2021 Q2	$7K	Hold	68	–	–	﹤0.01%	197
2021 Q1	$6K	Buy	+68	New	+$6.38K	﹤0.01%	195

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Corbenic Partners's DXCM Position: Q1 2022 in Review

Corbenic Partners sold out of DexCom (DXCM) in Q1 2022, closing a stake of 68 shares — an estimated $9K sold.

Corbenic Partners first reported a position in DXCM in Q1 2021 and held it in 4 quarters. The position peaked at $9K in Q4 2021. 861 funds tracked by Wall St. Rank hold DXCM as of Q1 2022.

Corbenic Partners reported no remaining DexCom position as of Q1 2022 after selling out during the quarter.
Corbenic Partners sold 68 DexCom shares in Q1 2022, an estimated $9K.
Corbenic Partners first reported a position in DexCom in Q1 2021 and held it in 4 quarters.
Corbenic Partners's DexCom position peaked at $9K in Q4 2021.
861 funds tracked by Wall St. Rank held DexCom as of Q1 2022.

Based on Corbenic Partners's 13F filing for Q1 2022, filed 14 Apr 2022.